GraniteShares ETF Trust GraniteShares News - NVDL | Aktien NASDAQ

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow FLEMINGTON, N.J., May 10 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc...

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12 FLEMINGTON, N.J., MAY 3 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc...

NovaDel Pharma's Third Foreign Patent Issued

NovaDel Pharma's Third Foreign Patent Issued FLEMINGTON, N.J., April 22 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL...

NovaDel CEO Interviews on Wall Street Reporter

NovaDel CEO Interviews on Wall Street Reporter First FDA Approval Filing to Occur Within Next Two Months; Five Tier One Drugs Entering Proof of...

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter FEMINGTON, N.J., April 15 /PRNewswire-FirstCall/ -- Gary Shangold, MD...

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting FLEMINGTON, N.J., April 14...

NovaDel Reports First Quarter 2004 Progress

NovaDel Reports First Quarter 2004 Progress FLEMINGTON, N.J., Apr. 7 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL...

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board FLEMINGTON, N.J., March 1...

NovaDel Raises $14 Million in Private Offering

NovaDel Raises $14 Million in Private Offering New Funding Will Accelerate Human Feasibility Studies of Four Top-Selling Drugs; First NDA Filing...

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study FLEMINGTON, N.J., Oct...

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

GraniteShares ETF Trust GraniteShares (NVDL)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

NVDL Nachrichten

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12

NovaDel Pharma's Third Foreign Patent Issued

NovaDel CEO Interviews on Wall Street Reporter

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting

NovaDel Reports First Quarter 2004 Progress

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board

NovaDel Raises $14 Million in Private Offering

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

GraniteShares ETF Trust GraniteShares (NVDL) News

GraniteShares ETF Trust GraniteShares (NVDL)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

NVDL Nachrichten

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12

NovaDel Pharma's Third Foreign Patent Issued

NovaDel CEO Interviews on Wall Street Reporter

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting

NovaDel Reports First Quarter 2004 Progress

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board

NovaDel Raises $14 Million in Private Offering

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen